Skip to content
Our 2022 Year in Review is now live.
  • Insights

      Weekly Bulletin

      Your weekly recap of news and analysis from the psychedelic sector.

      Read the Latest

      Research Review

      A monthly review of the most important psychedelics research.

      Review Archive

      News & Interviews

      The latest news from across the psychedelics space.

      Explore Now
  • Data

      Psychedelics Patent Trackers

      We track the latest patents and filings related to psilocybin, MDMA and DMT.

      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents
      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents

      Psychedelic Legalization & Decriminalization Tracker

      Mapping psychedelic drug policy reform across the United States

      Explore the Tracker
      New: Oregon Local Jurisdiction Tracker

      Psychedelics Drug Development Tracker

      From drug discovery to regulatory approval, we map drug development in psychedelics.

      Explore the Tracker
  • Companies

      Stocks & Companies Directory

      A directory of all the major psychedelics stocks, companies and ETFs.

      Access Directory

      Sector Landscape Map

      Explore the Psychedelic Sector Landscape visually using our new tool.

      Explore Now

      Stock Watchlist

      A one-stop overview of psychedelics stocks financial performance.

      Explore Now
  • Psychedelic Careers
  • Contact
Search
Close
Read more about the article MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

  • Post published:November 17, 2022
  • Post category:News/Press Release
Read more about the article BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics

BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics

  • Post published:August 1, 2022
  • Post category:News
Read more about the article Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines

Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines

  • Post published:July 29, 2022
  • Post category:Analysis/News
Read more about the article Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to be?

Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to be?

  • Post published:November 5, 2021
  • Post category:Analysis/News
Read more about the article Toronto University Health Network Launches Psychedelic Psychotherapy Research Centre

Toronto University Health Network Launches Psychedelic Psychotherapy Research Centre

  • Post published:September 27, 2021
  • Post category:News
Read more about the article Canadians Overwhelmingly Support Legal Access to Psilocybin-Assisted Therapy, Poll Reveals

Canadians Overwhelmingly Support Legal Access to Psilocybin-Assisted Therapy, Poll Reveals

  • Post published:August 4, 2021
  • Post category:News
Read more about the article Harvard Law School’s Petrie-Flom Center Launches Research Initiative on Psychedelics and the Law

Harvard Law School’s Petrie-Flom Center Launches Research Initiative on Psychedelics and the Law

  • Post published:June 30, 2021
  • Post category:Analysis/News
Read more about the article Atai Targets $2.3bn Valuation in Nasdaq IPO

Atai Targets $2.3bn Valuation in Nasdaq IPO

  • Post published:June 11, 2021
  • Post category:News
Read more about the article Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance

Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance

  • Post published:June 4, 2021
  • Post category:News/Op-ed
Read more about the article Psychedelics and Cannabis ETF Launches on NYSE Arca in First for the U.S.

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for the U.S.

  • Post published:June 1, 2021
  • Post category:News

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Psychedelic Stocks and Companies
  • News & Interviews
  • Psychedelic Sector Jobs
  • Data Bank

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

  • Psychedelic Alpha © 2022, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.